Latest / DDReg Knowledge Capsule / India's Pharma Shift from Generics to Innovation

Transcript

India's Pharma Shift from Generics to Innovation · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to Deidre Reg Knowledge Capsule. Right now, if you
• 0:03
  Speaker 1: open up your medicine cabinet, there is just a massive
• 0:07
  Speaker 1: statistical probability that an Indian pharmaceutical company had a hand
• 0:11
  Speaker 1: in making what's inside.
• 0:12
  Speaker 2: Oh, yeah, absolutely. It's almost a guarantee. Right.
• 0:15
  Speaker 1: Because for decades, they have basically been the undisputed kings
• 0:18
  Speaker 1: of the global generic drug market.
• 0:20
  Speaker 2: Yeah.
• 0:21
  Speaker 1: But today, they are quietly trying to pull off, I mean,
• 0:25
  Speaker 1: what has to be one of the biggest industrial pivots
• 0:27
  Speaker 1: in modern history.
• 0:29
  Speaker 2: It really is. It's a fundamental transformation of this critical
• 0:32
  Speaker 2: healthcare engine. We are basically witnessing an entire national industry
• 0:36
  Speaker 2: attempting to just completely rewrite its core DNA.
• 0:39
  Speaker 1: Which is exactly why we are dedicating this deep dive
• 0:41
  Speaker 1: to an incredibly insightful August 2026 article from D-Drake Pharma.
• 0:46
  Speaker 1: The piece is titled, India's Shift from Generic Manufacturing to Innovation,
• 0:50
  Speaker 1: What It Means for Global Regulatory Strategy. And our mission
• 0:53
  Speaker 1: today is to decode how India is transitioning from being
• 0:56
  Speaker 1: the the pharmacy of the world, you know, the master
• 0:58
  Speaker 1: of high volume, affordable generic medicines into a true powerhouse
• 1:02
  Speaker 1: of ground up pharmaceutical innovation.
• 1:04
  Speaker 2: Right. And we're looking at what this actually means for
• 1:07
  Speaker 2: international supply chains, for patients globally. And honestly, for the
• 1:12
  Speaker 2: incredibly dense regulatory strategies that are required to actually put
• 1:16
  Speaker 2: these new drugs on the market.
• 1:18
  Speaker 1: Because to really appreciate the scale of this pivot, we
• 1:22
  Speaker 1: have to recognize the empire that already exists. I mean,
• 1:25
  Speaker 1: Indian pharmaceutical companies have built this absolute fortress on traditional
• 1:29
  Speaker 1: manufacturing strengths.
• 1:31
  Speaker 2: Yeah, they really have. They possess just this unmatched formulation expertise.
• 1:35
  Speaker 2: They absolutely dominate the production of active pharmaceutical ingredients or APIs. Right.
• 1:40
  Speaker 2: And they have constructed this massive cost-effective infrastructure. They act
• 1:45
  Speaker 2: as this vital load-bearing pillar for global healthcare simply by
• 1:49
  Speaker 2: sheer volume alone.
• 1:51
  Speaker 1: Okay, let's unpack this because this is where the strategy seems, well,
• 1:56
  Speaker 1: It seems a bit counterintuitive to me.
• 1:57
  Speaker 2: How so?
• 1:58
  Speaker 1: Well, if India has already mastered large scale cost effective
• 2:02
  Speaker 1: production and they are essentially an indispensable guaranteed part of
• 2:05
  Speaker 1: global supply chains. Why fix what isn't broken? Like why
• 2:10
  Speaker 1: risk shifting away from guaranteed massive generic volume when they
• 2:15
  Speaker 1: essentially hold a royal flush in that specific game?
• 2:19
  Speaker 2: Well, the problem is that the rules of that specific
• 2:21
  Speaker 2: game are they're eroding.
• 2:23
  Speaker 1: Okay.
• 2:24
  Speaker 2: The generic market is facing severe margin compression right now.
• 2:28
  Speaker 2: It is incredibly crowded, it's heavily fragmented, and it is
• 2:31
  Speaker 2: just heavily commoditized.
• 2:32
  Speaker 1: So it's a race to the bottom.
• 2:34
  Speaker 2: Exactly. When you are producing standard traditional generics, you are
• 2:38
  Speaker 2: locked in this relentless race to the bottom on price.
• 2:42
  Speaker 2: And the DGREG Pharma article points out that secure, long-term,
• 2:46
  Speaker 2: high-value growth companies really have to escape that commoditization trap.
• 2:50
  Speaker 1: I see.
• 2:51
  Speaker 2: The real future opportunities, the ones that actually pay off,
• 2:54
  Speaker 2: they lie in products that demand a significantly higher degree
• 2:58
  Speaker 2: of scientific and clinical expertise.
• 3:00
  Speaker 1: So they aren't just turning off the generic manufacturing machine.
• 3:03
  Speaker 2: No, no, not at all.
• 3:04
  Speaker 1: They are using that massive, highly efficient manufacturing base as
• 3:07
  Speaker 1: like a financial and logistical launchpad. They're moving from just
• 3:11
  Speaker 1: flawlessly copying the recipe to actually discovering and writing new recipes.
• 3:15
  Speaker 2: That is a great way to put it, yeah.
• 3:17
  Speaker 1: And the source material maps out the scientific evolution on
• 3:20
  Speaker 1: the ground, highlighting three distinct areas of innovation.
• 3:24
  Speaker 2: And the leap in complexity, well, it really begins with biosimilars.
• 3:28
  Speaker 1: Right. So moving into biosimilars represents a complete departure from
• 3:32
  Speaker 1: traditional chemical synthesis altogether.
• 3:34
  Speaker 2: Wait, really?
• 3:35
  Speaker 1: Yeah. So instead of just combining raw chemical ingredients in
• 3:38
  Speaker 1: a vat to create a small molecule drug, you are
• 3:41
  Speaker 1: actually programming living mammalian cells or microorganisms into To secrete
• 3:47
  Speaker 1: a specific, highly complex therapeutic protein.
• 3:51
  Speaker 2: Oh, wow. So moving from standard generics to biosimilars, it
• 3:55
  Speaker 2: isn't just upgrading your factory equipment. It's like going from
• 3:58
  Speaker 2: assembling a simple, identical piece of flat pack furniture where,
• 4:01
  Speaker 2: you know, every screw and board is exactly the same
• 4:03
  Speaker 2: every single time to trying to bake a highly complex
• 4:08
  Speaker 2: Michelin star souffle.
• 4:09
  Speaker 1: Yes.
• 4:10
  Speaker 2: And in the souffle, the ingredients are technically alive. And
• 4:13
  Speaker 2: they're highly sensitive to literally any change in the environment.
• 4:16
  Speaker 2: Like you can't just chemically synthesize it. You actually have
• 4:19
  Speaker 2: to cultivate it. What's fascinating here is how perfectly that
• 4:22
  Speaker 2: analogy captures the regulatory reality of biologic.
• 4:25
  Speaker 1: Oh, really?
• 4:26
  Speaker 2: Yeah. Because those products are synthesized by living cells. They
• 4:31
  Speaker 2: are exquisitely sensitive to minute changes in temperature or pH
• 4:35
  Speaker 2: or even the dissolved oxygen in the bioreactor.
• 4:38
  Speaker 1: Just tiny fluctuations. Exactly.
• 4:39
  Speaker 2: Exactly. If a parameter shifts by even a fraction of
• 4:43
  Speaker 2: a degree, the protein might fold incorrectly. And if that happens,
• 4:47
  Speaker 2: it might lose its therapeutic efficacy, or worse, it could
• 4:51
  Speaker 2: trigger a dangerous immune response in the patient.
• 4:53
  Speaker 1: That sounds terrifying.
• 4:54
  Speaker 2: It is, which is why regulators know this. Consequently, you
• 4:57
  Speaker 2: can't just prove the final vial has the same molecular
• 5:00
  Speaker 2: weight as the reference drug. You have to submit advanced
• 5:03
  Speaker 2: structural analysis, extensive cell line characterization, deep comparability studies, and
• 5:09
  Speaker 2: and robust clinical trial evidence to prove it behaves exactly
• 5:12
  Speaker 2: the same way in a human body.
• 5:13
  Speaker 1: That is a staggering leap from simply demonstrating bioequivalence for
• 5:17
  Speaker 1: like a generic ibuprofen tablet.
• 5:19
  Speaker 2: Oh, absolutely. It's a completely different universe of compliance.
• 5:22
  Speaker 1: But the innovation isn't strictly limited to growing live cells, right?
• 5:26
  Speaker 1: Because even when we look at traditional chemical molecules, the
• 5:31
  Speaker 1: delivery mechanisms themselves are becoming like these microscopic feats of engineering.
• 5:36
  Speaker 2: Hmm.
• 5:37
  Speaker 1: The article outlines complex generics as a major focal point here.
• 5:41
  Speaker 2: Yeah, complex generics take established molecules and apply highly sophisticated
• 5:45
  Speaker 2: delivery technologies. So we are looking at things like liposomal formulations,
• 5:50
  Speaker 2: where the drug is encapsulated in a lipid bilayer, so
• 5:53
  Speaker 2: it targets specific tissues, or complex autoinjector pens for autoimmune diseases,
• 5:58
  Speaker 2: or highly specialized modified release mechanisms.
• 6:01
  Speaker 1: Yeah, because when you're dealing with a modified release formulation,
• 6:04
  Speaker 1: the analytical methods have to be completely bulletproof.
• 6:07
  Speaker 2: Oh, 100%.
• 6:08
  Speaker 1: Like if you have a pill that's designed to release
• 6:10
  Speaker 1: a powerful cardiovascular drug slowly over, say, 24 hours, and
• 6:14
  Speaker 1: a microscopic manufacturing flaw causes the coating to dissolve immediately,
• 6:19
  Speaker 1: the patient receives a massive, potentially fatal dose all at once.
• 6:22
  Speaker 1: The engineering tolerances required to prevent that kind of dose
• 6:25
  Speaker 1: dumping are just razor thin.
• 6:27
  Speaker 2: And that razor thin tolerance, it demands a completely overhauled
• 6:32
  Speaker 2: quality management system. Right. I mean, the analytical chemistry required
• 6:36
  Speaker 2: just to prove you built the complex generic correctly, it
• 6:39
  Speaker 2: often borders on basic research.
• 6:41
  Speaker 1: Yeah.
• 6:42
  Speaker 2: And that mechanical and analytical complexity is really just the
• 6:45
  Speaker 2: stepping stone to the third area of focus, which is
• 6:48
  Speaker 2: advanced therapies and novel medicines.
• 6:51
  Speaker 1: This is where we cross into territory that sounds a
• 6:53
  Speaker 1: little bit like science fiction to me.
• 6:54
  Speaker 2: Yeah, it really does.
• 6:55
  Speaker 1: I mean, Indian companies are heavily investing in translational medicine,
• 6:59
  Speaker 1: gene and cell therapies, precision medicine. that's tailored to specific
• 7:04
  Speaker 1: patient biomarkers, and entirely novel molecules discovered through AI-assisted platforms,
• 7:11
  Speaker 1: they are using machine learning to predict molecular binding affinities,
• 7:16
  Speaker 1: which is compressing discovery timelines from years down to basically months.
• 7:19
  Speaker 2: It's incredible, and this raises a really important question regarding
• 7:22
  Speaker 2: how these scientific leaps intersect with market access. As the
• 7:26
  Speaker 2: underlying science of the therapies changes so drastically, the traditional
• 7:30
  Speaker 2: rulebook for getting a drug approved It completely shatters.
• 7:33
  Speaker 1: Yeah. So we are transitioning from the hard science of
• 7:37
  Speaker 1: discovering the drugs to the intense, really high-stakes strategy of
• 7:41
  Speaker 1: navigating this regulatory shockwave.
• 7:43
  Speaker 2: Exactly.
• 7:43
  Speaker 1: Because the traditional generic approach was a relatively known quantity.
• 7:47
  Speaker 1: You demonstrate production capability, you run a bioequivalent study on
• 7:51
  Speaker 1: healthy volunteers, and you submit the data. The entire regulatory
• 7:54
  Speaker 1: focus was pretty much just on manufacturing consistency.
• 7:57
  Speaker 2: Right. But the innovation-driven pipeline, it operates in a totally
• 8:01
  Speaker 2: different universe. When you are bringing a novel medicine or
• 8:05
  Speaker 2: a complex biologic to a heavily regulated market like the U.S.
• 8:08
  Speaker 2: or Europe, the pathway is grueling.
• 8:11
  Speaker 1: I can imagine.
• 8:12
  Speaker 2: It starts at foundational scientific discovery, progresses into complex, multi-phase
• 8:16
  Speaker 2: clinical trials in patient populations to prove actual safety and
• 8:21
  Speaker 2: efficacy from scratch. And it relies entirely on an elite
• 8:24
  Speaker 2: CMC strategy.
• 8:26
  Speaker 1: And just to clarify for everyone, CMC being chemistry manufacturing
• 8:29
  Speaker 1: and controls.
• 8:29
  Speaker 2: Correct.
• 8:30
  Speaker 1: Thank you.
• 8:30
  Speaker 2: And with complex biological products, there is a fundamental regulatory maxim,
• 8:34
  Speaker 2: the process is the product.
• 8:35
  Speaker 1: Okay. What does that mean exactly?
• 8:37
  Speaker 2: It means you cannot separate the therapeutic from how it
• 8:40
  Speaker 2: was made. If you change a filter supplier or you
• 8:44
  Speaker 2: modify the purification steps, regulators may view it as an
• 8:47
  Speaker 2: entirely new drug.
• 8:48
  Speaker 1: Just from changing a filter.
• 8:49
  Speaker 2: Exactly. Yeah. Which means requiring you to repeat clinical trials.
• 8:53
  Speaker 1: Oh, my gosh.
• 8:54
  Speaker 2: So CMC strategy is about anticipating every single variable in
• 8:58
  Speaker 2: your manufacturing process, proving to the FDA that you have
• 9:02
  Speaker 2: absolute control over those variables, and documenting it flawlessly in
• 9:06
  Speaker 2: your ECTD.
• 9:07
  Speaker 1: Which is the Electronic Common Technical Document Submission.
• 9:10
  Speaker 2: Right.
• 9:10
  Speaker 1: Which totally explains why global regulators have set the bar
• 9:14
  Speaker 1: at basically the absolute ceiling. I mean, if Indian pharma
• 9:17
  Speaker 1: companies want to target these premium regulated markets... They have
• 9:20
  Speaker 1: to demonstrate quality systems that can withstand forensic-level scrutiny. The
• 9:25
  Speaker 1: DGREG Pharma article details some of these non-negotiables. It mentions
• 9:29
  Speaker 1: strict GMP compliance, continuous PV or pharmacovigilance risk management to
• 9:35
  Speaker 1: monitor adverse events in the real world, and this massive
• 9:38
  Speaker 1: emphasis on LCOA plus data integrity principles.
• 9:41
  Speaker 2: Yes. LCOA plus is truly the bedrock of modern regulatory compliance. Right. Attributable, legible, contemporaneous, original,
• 9:51
  Speaker 2: and accurate.
• 9:52
  Speaker 1: Okay.
• 9:52
  Speaker 2: Placed complete, consistent, enduring, and available.
• 9:55
  Speaker 1: That is a lot of adjectives.
• 9:57
  Speaker 2: It is. But in practice, this means if an object
• 9:59
  Speaker 2: is operator in a biomanufacturing facility changes a bioreactor setting
• 10:04
  Speaker 2: at 2.0 a.m. on a Sunday. Yeah. The FDA requires
• 10:08
  Speaker 2: an unalterable cryptographically secure digital footprint. of that exact keystroke
• 10:14
  Speaker 2: 10 years from now.
• 10:14
  Speaker 1: Wow, 10 years.
• 10:16
  Speaker 2: Yeah, you cannot just write a temperature log on a
• 10:18
  Speaker 2: clipboard anymore. The data systems must be inherently tamper-proof.
• 10:22
  Speaker 1: So what does this all mean? Historically, compliance felt a
• 10:25
  Speaker 1: bit like taking a final exam, right? You passed the
• 10:28
  Speaker 1: facility inspection, you got your approval letter, you moved on.
• 10:31
  Speaker 2: Right.
• 10:32
  Speaker 1: But looking at continuous pharmacovigilance and stringent LFOA plus standards,
• 10:36
  Speaker 1: has regulatory compliance shifted from being a basic legal hurdle
• 10:40
  Speaker 1: to Into an actual competitive advantage.
• 10:43
  Speaker 2: Oh, it has become the primary competitive advantage. Really?
• 10:45
  Speaker 1: Yeah.
• 10:46
  Speaker 2: Regulatory lifecycle management is no longer a one-time event. It
• 10:49
  Speaker 2: is a continuous development to commercial strategy. Once an innovative
• 10:52
  Speaker 2: drug is approved, the work has honestly barely started. You
• 10:56
  Speaker 2: have to manage post-approval manufacturing updates, geographical expansions, safety signal monitoring,
• 11:02
  Speaker 2: and ongoing regulatory commitments.
• 11:05
  Speaker 1: It never ends.
• 11:05
  Speaker 2: It never ends. And companies possessing a seamless, highly mature
• 11:10
  Speaker 2: regulatory infrastructure, they can adapt to these inevitable changes rapidly.
• 11:15
  Speaker 2: They secure market access faster and they maintain their commercial
• 11:18
  Speaker 2: footing far more securely than a competitor who treats compliance
• 11:22
  Speaker 2: as just an afterthought.
• 11:24
  Speaker 1: Well, the domestic regulatory environment in India is being forced
• 11:27
  Speaker 1: to evolve alongside the industry to actually support this. The
• 11:30
  Speaker 1: article notes the Central Drug Standard Control Organization, the CDSEO,
• 11:34
  Speaker 1: is implementing some pretty sweeping reforms. They're talking about moving
• 11:37
  Speaker 1: to digital regulatory processes, establishing faster approval pathways for innovative drugs,
• 11:43
  Speaker 1: and really aligning their oversight protocols with stringent international standards.
• 11:46
  Speaker 2: Which is a massive undertaking.
• 11:48
  Speaker 1: Well, right. And wait, let me challenge that for a second,
• 11:50
  Speaker 1: because the CDSCO pushing for digital processes and international alignment, well,
• 11:55
  Speaker 1: that sounds fantastic in a press release.
• 11:57
  Speaker 2: Yeah.
• 11:57
  Speaker 1: But we are talking about digitizing a massive, historically dense
• 12:01
  Speaker 1: bureaucracy in a country of 1.4 billion people.
• 12:05
  Speaker 2: Right.
• 12:05
  Speaker 1: That doesn't happen overnight just because a policy was updated, right?
• 12:10
  Speaker 1: How do they actually ensure that global partners and, more importantly,
• 12:14
  Speaker 1: global regulators like the EMA and the FDA actually trust
• 12:18
  Speaker 1: this new digital framework?
• 12:20
  Speaker 2: That skepticism is entirely warranted. Trust isn't generated by just
• 12:24
  Speaker 2: installing new software, right?
• 12:26
  Speaker 1: Exactly.
• 12:26
  Speaker 2: It is generated by a demonstrable culture shift. The CDSCO
• 12:30
  Speaker 2: is transitioning from a traditional policing mindset to more of
• 12:33
  Speaker 2: an enabling mindset. similar to how the FDA approaches breakthrough therapies.
• 12:37
  Speaker 1: Okay, so more collaborative.
• 12:38
  Speaker 2: Yes, they are actively recruiting specialized talent who actually understand
• 12:42
  Speaker 2: advanced biologics, and they are increasing their participation in international
• 12:46
  Speaker 2: harmonization initiatives. But you are correct, the burden of proof
• 12:49
  Speaker 2: remains incredibly heavy. A robust, internationally respected domestic regulatory framework
• 12:55
  Speaker 2: is the absolute prerequisite. If global stakeholders don't have absolute
• 12:59
  Speaker 2: faith in the oversight occurring within India's borders, They will
• 13:03
  Speaker 2: never trust the advanced therapies being exported from them.
• 13:06
  Speaker 1: Right. Because seeing the goal line and rewriting the rulebook
• 13:09
  Speaker 1: doesn't automatically clear the path for you.
• 13:11
  Speaker 2: No.
• 13:11
  Speaker 1: There are massive structural roadblocks preventing Indian pharma from simply
• 13:16
  Speaker 1: dominating this innovation space tomorrow. I mean, transition requires a
• 13:21
  Speaker 1: staggering amount of capital and specialized infrastructure.
• 13:23
  Speaker 2: The required R & D investment is probably the most
• 13:26
  Speaker 2: immediate hurdle. Competing in the generic space requires capital for
• 13:30
  Speaker 2: manufacturing scale. But competing in the innovation space requires patient capital.
• 13:35
  Speaker 1: Patient capital. I like that.
• 13:36
  Speaker 2: Yeah. Developing a novel molecule or a complex gene therapy,
• 13:40
  Speaker 2: it can take a decade of continuous cash burn before
• 13:42
  Speaker 2: a single dollar of revenue is generated. Right. Indian companies
• 13:46
  Speaker 2: must dramatically increase their R & D spend, invest in
• 13:49
  Speaker 2: world-class clinical development services, and honestly attract elite scientific talent
• 13:54
  Speaker 2: away from established Western hubs.
• 13:56
  Speaker 1: And then there is the challenge of building that advanced
• 13:59
  Speaker 1: technology regulatory expertise internally, because it is one thing to
• 14:03
  Speaker 1: hire brilliant scientists who understand the molecular mechanism of a
• 14:06
  Speaker 1: new cancer drug. It is another entirely to have, to
• 14:10
  Speaker 1: have specialists who can fluently speak the nuanced, highly specific
• 14:14
  Speaker 1: language of global regulators. Navigating an FDA biologics license application
• 14:21
  Speaker 1: requires a very different skill set than filing a standard
• 14:25
  Speaker 1: generic drug application.
• 14:27
  Speaker 2: Absolutely. And we also have to look at the broader ecosystem,
• 14:29
  Speaker 2: specifically the connective tissue between industry and academia.
• 14:33
  Speaker 1: Oh, right.
• 14:33
  Speaker 2: If you examine globally dominant innovation hubs, places like Kendall
• 14:37
  Speaker 2: Square in Boston or the Golden Triangle in the UK,
• 14:39
  Speaker 2: they thrive because there is a porous, constant exchange of
• 14:42
  Speaker 2: ideas and talent between major universities, agile biotech startups, and
• 14:47
  Speaker 2: Massive pharmaceutical manufacturers. Right.
• 14:49
  Speaker 1: They all feed off each other.
• 14:50
  Speaker 2: Precisely. India possesses incredible academic institutions, but the pipeline transferring
• 14:55
  Speaker 2: early stage academic research into commercial pharmaceutical development needs significant
• 14:59
  Speaker 2: strengthening to foster a true innovation ecosystem.
• 15:02
  Speaker 1: Here's where it gets really interesting for the listener, especially
• 15:05
  Speaker 1: if you are sitting in a boardroom right now looking
• 15:08
  Speaker 1: to partner with an Indian manufacturer. Your entire vendor qualification
• 15:13
  Speaker 1: checklist just became completely obsolete.
• 15:16
  Speaker 2: Oh, yeah, totally.
• 15:17
  Speaker 1: Like 10 years ago, the primary questions were about capacity,
• 15:21
  Speaker 1: like how many million doses can your facility press in
• 15:23
  Speaker 1: a month and at what cost?
• 15:25
  Speaker 2: Right.
• 15:26
  Speaker 1: Today, evaluating an Indian pharmaceutical partner requires auditing their regulatory maturity,
• 15:32
  Speaker 1: interrogating their quality management systems, assessing their clinical development capabilities,
• 15:39
  Speaker 1: and looking really deeply into their proprietary innovation pipeline.
• 15:43
  Speaker 2: If we connect this to the bigger picture, achieving robust
• 15:46
  Speaker 2: global market access in today's environment demands marrying scientific advancement
• 15:51
  Speaker 2: with elite regulatory strategy from day zero.
• 15:54
  Speaker 1: Day zero, yeah.
• 15:55
  Speaker 2: For Indian companies looking to expand their footprint internationally with
• 15:58
  Speaker 2: these new products, they cannot wait until a biologic is
• 16:00
  Speaker 2: successfully formulated in a lab to start thinking about the FDA. Right.
• 16:04
  Speaker 1: It's too late by then.
• 16:05
  Speaker 2: Way too late. They have to integrate CMC capabilities into
• 16:09
  Speaker 2: the initial discovery phase. They have to design their clinical
• 16:12
  Speaker 2: trials with global submission requirements in mind. Regulatory strategy is
• 16:16
  Speaker 2: no longer the caboose of the development train. It is
• 16:19
  Speaker 2: the engine. Wow.
• 16:20
  Speaker 1: We are really watching a total industrial metamorphosis here. An
• 16:25
  Speaker 1: entire sector is journeying from the incredible logistics of mass-volume, cost-effective,
• 16:31
  Speaker 1: generic manufacturing straight into the frontier of AI drug discovery
• 16:36
  Speaker 1: and navigating the razor-thin margins of error in complex biologics.
• 16:40
  Speaker 2: It is a pivot that will radically alter the workflows,
• 16:43
  Speaker 2: the investment strategies, and the market dynamics of global healthcare.
• 16:47
  Speaker 2: The organizations that recognize this shift early, the ones that
• 16:50
  Speaker 2: proactively adapt their regulatory and development frameworks today, they will
• 16:54
  Speaker 2: be the architects of the pharmaceutical landscape for the next
• 16:57
  Speaker 2: three decades.
• 16:58
  Speaker 1: They really are moving from efficiently manufacturing the world's medicine
• 17:02
  Speaker 1: to fundamentally shaping the next generation of healthcare technology.
• 17:05
  Speaker 2: Yeah.
• 17:05
  Speaker 1: And that leaves us with a truly fascinating dynamic to ponder.
• 17:08
  Speaker 2: Oh, absolutely.
• 17:09
  Speaker 1: If India successfully completes this transition, right, if they evolve
• 17:14
  Speaker 1: from being the pharmacy of the world to the laboratory
• 17:16
  Speaker 1: of the world, how will this shift the geopolitical balance
• 17:20
  Speaker 1: of healthcare?
• 17:20
  Speaker 2: It's a huge question.
• 17:22
  Speaker 1: It is. As advanced therapies, complex biologics, and AI-discovered drugs
• 17:26
  Speaker 1: increasingly emerge from the East... Will the traditional pharmaceutical strongholds
• 17:30
  Speaker 1: in the West find themselves relying on India not just
• 17:34
  Speaker 1: for their supply chain logistics and active ingredients, but for
• 17:37
  Speaker 1: the fundamental patented blueprints of life-saving cures?
• 17:41
  Speaker 2: The implications for global health reliance, intellectual property and international
• 17:44
  Speaker 2: trade are truly profound.
• 17:47
  Speaker 1: It's going to be absolutely incredible to watch it unfold.
• 17:49
  Speaker 1: Thank you all for joining us on this deep dive
• 17:51
  Speaker 1: into the shifting tectonic plates of global pharma. Keep asking questions.
• 17:56
  Speaker 1: Keep looking beneath the surface and we will catch you
• 17:58
  Speaker 1: next time.